JMP Securities reiterates Evelo Biosciences Inc. [EVLO] rating to Outperform and sets new price target at $27
JMP Securities maintained its Evelo Biosciences Inc. [NASDAQ:EVLO] rating to the equivalent of Outperform but changed the price target to $27, in a research note dated December 30, 2020. That figure represents around a 139.57% premium from where the company’s shares closed on Tuesday. Some new analysts also started their coverage, with JMP Securities’s analysts […]
